46 research outputs found

    Turismo sustentável nos empreendimentos turísticos em São Tomé e Príncipe

    Get PDF
    O presente trabalho de investiga√ß√£o tem como objetivo geral analisar a ado√ß√£o de pr√°ticas de responsabilidade social e sustentabilidade nos empreendimentos tur√≠sticos sediados em S√£o Tom√© e Pr√≠ncipe. Para dar resposta ao principal objetivo aplicou-se como instrumento de recolha de dados um inqu√©rito por question√°rio aos 21 empreendimentos tur√≠sticos localizados nas ilhas de S√£o Tom√© e do Pr√≠ncipe. O instrumento encontra-se estruturado nas seguintes tr√™s partes: a primeira inclui quest√Ķes para a carateriza√ß√£o do empreendimento; a segunda incorpora quest√Ķes sobre a ado√ß√£o de pr√°ticas de responsabilidade social e sustentabilidade nos empreendimentos tur√≠sticos; a terceira incorpora quest√Ķes para analisar o conhecimento de medidas de responsabilidade social e sustentabilidade no setor tur√≠stico, por parte dos respons√°veis (diretores/gestores) pelo empreendimento tur√≠stico. Como metodologia de investiga√ß√£o utilizada recorreu-se a uma an√°lise descritiva explorat√≥ria. Os principais resultados apontam para uma preocupa√ß√£o dos intervenientes para a aplica√ß√£o de pr√°ticas de responsabilidade social e sustentabilidade dada a import√Ęncia atribu√≠da pelos mesmos (m√©dia de 4,4 e desvio padr√£o 0,607). Por√©m, verificou-se que ainda n√£o √© satisfat√≥rio a implementa√ß√£o destas (m√©dia de 3,3 e desvio padr√£o 0,898), nomeadamente as relacionadas com os indicadores de sustentabilidade ambiental. Atrav√©s do coeficiente de correla√ß√£o de Spearman pode ainda dizer-se que existe uma correla√ß√£o moderada e estatisticamente significativa a 5% (r=0,529; p-value=0,014) entre a implementa√ß√£o das pr√°ticas de responsabilidade social e sustentabilidade e a import√Ęncia atribu√≠da √†s mesmas.info:eu-repo/semantics/publishedVersio

    Mieloma m√ļltiplo em uma cadela de 10 anos

    Get PDF
    Background: The malignant neoplasms, in general, constitute one of the main causes of death in dogs and cats. The multiple myeloma is a neoplasm characterized by the monoclonal proliferation of plasma cells in the bone marrow, causing several systemic symptoms and it is rare in pets, representing less than 1% of the malignant neoplasms in these animals. It usually occurs in older dogs. Thus, the purpose of this report was to describe a case of multiple myeloma in a 10-year-old poodle dog, occurred in the Veterinary Hospital Unit of the State University of Ceará.Case: A 10-year-old Poodle bitch was admitted in the Veterinary Hospital Unit of the State University of Ceará presenting lump erythematosus, alopecic, soft and ulcers in the region of the digits of the left front leg, pain and lameness. The blood count evidenced normocytic and normochromic anemia, presence of rouleaux, lymphopenia and monocytopenia, and the biochemical exams have demonstrated an elevated value of alanine aminotransferase (ALT). The cytology of the nodule indicated probable diagnosis of plasma cell neoplasm and radiographic examination showed the presence of bone lysis, and therefore the patient underwent amputation of the affected limb surgery. A biopsy of the nodule indicated neoplastic proliferation, with an arrange compatible to plasmacytoma of cleaved type. A follow-up consultation was realized 30 days after surgery, and 2 new nodules appeared in the superior lip region and close to the surgery site. A new blood count indicated anemia with presence of rouleaux, thrombocytopenia, leucopenia, lymphopenia and monocytopenia, and the biochemical results showed a discrete diminution of aspartate aminotransferase(AST) and a considerable increase on the alkaline phosphatase levels. The cytology of the new nodules indicated plasmacytoma, and was realized a myelogram, that showed dysplastic marrow plasma cells, with more than 20% of plasma cells.Discussion: In the present case, the patient’s lump grew rapidly with bleeding and ulcer formation. The animal presented bone involvement, which characterizes the most suggestive sign of multiple myeloma. Justified by the stimulating factor of osteoclasts, promoting bone lysis, which can cause pathological fractures and pain. The amputation was a partial treatment to attenuates the discomfort and pain presented by the patient. The appearance of new nodules stimulated a more detailed investigation for multiple myeloma. The enzyme AST presented a discrete diminution, and ALT initially was higher than normal, but then returned to normal values. So, the elevated activity of alkaline phosphatase directed the suspects to multiple myeloma, since the activity of AST and ALT was normal, the alkaline phosphatase level was ligated to bone diseases. The rouleaux was constant at the hemograms, this is justified by the excess of immunoglobulins produced in marrow. Based on the chart presented by the patient, the bone marrow was punctured for myelogram. The symptoms displayed by the animal along with the cytological analysis, histopathological, hematological, biochemical and with myelogram indicated diagnosis of multiple myeloma. Other exams could be investigated, for example, detection of Bence Jones proteinuria, serum calcium dosage and inmunoelectroforesis for determination of the type of immunoglobulin produced by the plasma cells in the bone marrow. The definitive diagnostic was established approximately three months after the first consult, emphasizing the importance of a multiple myeloma differential diagnostic in case of plasma cell neoplasm

    Proteolytic potential of enzymes produced by candida parapsilosis and rhodotorula. Mucilaginosa isolated from liquid whey

    Get PDF
    The search for yeast with proteolytic activity that can be explored in technology and product innovation was the objective of this study to isolate and identify strains present in liquid whey and evaluate the proteolytic activity of isolates. From the isolated strains were selected for molecular identification, those with proteolytic activity. Verification of proteolytic activity was performed on milk agar and visualized by a translucent halo. Four strains belonging to two yeast species were identified as protease producers. Whey is promising in microbial sources of biotechnological interest and C. parapsilosis (ES01) and R. mucilaginosa (ES04) strains were good protease producers in commercial agar-like milk agar. These results indicate the proteolytic potentiality of strains isolated from whey.Fil: Monte, Aline Marques. Universidade Federal Do Piaui.; BrasilFil: Matos da Silva, Ana Karoline. Universidade Federal Do Piaui.; BrasilFil: Dourado Rodrigues, Aline Maria. Universidade Federal Do Piaui.; BrasilFil: Muratori Costa, Luciana. Universidade Federal Do Piaui.; BrasilFil: Sousa Santos, André Luis. Universidade Federal do Rio de Janeiro; BrasilFil: Gomes Abreu Bacelar, Rafael. Universidade Federal Do Piaui.; BrasilFil: de Sousa Ramos, Lívia. Universidade Federal do Rio de Janeiro; BrasilFil: Folmer Correa, Ana Paula. Universidade Federal de Roraima; BrasilFil: Brandelli, Adriano. Universidade Federal do Rio Grande do Sul; BrasilFil: Pereyra, Carina Maricel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas, Fisicoquímicas y Naturales. Departamento de Microbiología e Inmunología; ArgentinaFil: Sanches Muratori, Maria C.. Universidade Federal Do Piaui.; Brasi

    A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America

    Get PDF
    Background: Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants spectrum of patients with suspected LS in Latin America. Methods: Eleven LS hereditary cancer registries and 34 published LS databases were used to identify unrelated families that fulfilled the Amsterdam II (AMSII) criteria and/or the Bethesda guidelines or suggestive of a dominant colorectal (CRC) inheritance syndrome. Results: We performed a thorough investigation of 15 countries and identified 6 countries where germline genetic testing for LS is available and 3 countries where tumor testing is used in the LS diagnosis. The spectrum of pathogenic MMR variants included MLH1 up to 54%, MSH2 up to 43%, MSH6 up to 10%, PMS2 up to 3% and EPCAM up to 0.8%. The Latin America MMR spectrum is broad with a total of 220 different variants which 80% were private and 20% were recurrent. Frequent regions included exons 11 of MLH1 (15%), exon 3 and 7 of MSH2 (17 and 15%, respectively), exon 4 of MSH6 (65%), exons 11 and 13 of PMS2 (31% and 23%, respectively). Sixteen international founder variants in MLH1, MSH2 and MSH6 were identified and 41 (19%) variants have not previously been reported, thus representing novel genetic variants in the MMR genes. The AMSII criteria was the most used clinical criteria to identify pathogenic MMR carriers although microsatellite instability, immunohistochemistry and family history are still the primary methods in several countries where no genetic testing for LS is available yet. Conclusion: The Latin America LS pathogenic MMR variants spectrum included new variants, frequently altered genetic regions and potential founder effects, emphasizing the relevance implementing Lynch syndrome genetic testing and counseling in all of Latin America countries.Radium Hospital Foundation (Oslo, Norway) in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript, Helse S√łr-√ėst (Norway) in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript, the French Association Recherche contre le Cancer (ARC) in the analysis, and interpretation of data, the Groupement des Entreprises Fran√ßaises dans la Lutte contre le Cancer (Gefluc) in the analysis, and interpretation of data, the Association Nationale de la Recherche et de la Technologie (ANRT, CIFRE PhD fellowship to H.T.) in the analysis, and interpretation of data and by the OpenHealth Institute in the analysis, and interpretation of data. Barretos Cancer Hospital received financial support by FINEP-CT-INFRA (02/2010)info:eu-repo/semantics/publishedVersio

    Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Get PDF
    Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio